News · 26 weeks141-33%
2025-12-142026-06-07
Mix5790d
- Other31(54%)
- Insider13(23%)
- SEC Filings8(14%)
- Earnings3(5%)
- Analyst1(2%)
- Dividends1(2%)
Latest news
25 items- PRLilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopauseIn ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant weight across all stages of menopause, despite the additional challenge of living with type 2 diabetesAcross studies, women taking Foundayo saw meaningful reductions in their waist circumference, a measure associated with reduced abdominal fat and cardiometabolic riskINDIANAPOLIS, June 7, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide), today announced results demonstrating that women with obesity or overweight who took the highest dose of Foundayo experienced signi
- PRLilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complicationsIn TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesityIn addition to weight loss, retatrutide reduced knee osteoarthritis pain by up to 4.3 points (73.1%) and moderate-to-severe obstructive sleep apnea severity by up to 36.1 events per hour (60.6%)In TRANSCEND-T2D-1, participants on retatrutide achieved A1C reductions of up to 2.0% and weight loss of up to 36.6 lbs (16.8%) at 40 weeks, with up to 46% achieving a normal A1CINDIANAPOLIS, June 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), tod
- PRLilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to ExplodeDENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer. The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary Session at the 2026 ASCO Annual Meeting and will be simultaneously published in The New England Journal of Medicine. For investors, the
- PRLilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity carePhase 3 ACHIEVE results showed Foundayo, an oral GLP-1 taken without food or water restrictions, outperformed oral semaglutide and dapagliflozin in type 2 diabetes, reinforcing its potential to redefine oral incretin therapyNew analyses of the ATTAIN program highlight Foundayo's profile in patient populations central to the future of cardiometabolic care, including women at every stage of menopausePivotal Phase 3 results showed retatrutide, a first-in-class triple receptor agonist, delivered powerful results in obesity, type 2 diabetes and other complicationsINDIANAPOLIS, May 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide), Mounjaro (tirzepatide
- PRFoundayo and Zepbound now covered for millions of AmericansCVS Caremark begins covering Foundayo June 1 and resumes Zepbound coverage by October 1 Eligible patients may pay as low as $25 a month for their medicineINDIANAPOLIS, May 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced an access milestone in obesity care: all three of the nation's largest pharmacy benefit managers (PBMs) will cover Lilly's full obesity medicine portfolio. This significantly expands the number of Americans who can access FDA-approved options through their existing insurance."For too long, effective obesity treatment has been out of reach for the people who need it," said Ilya Yuffa, executive vice president and president of Lilly USA and global cust
- PRLilly to participate in Goldman Sachs 47th Annual Global Healthcare ConferenceINDIANAPOLIS, May 27, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health, will take part in a fireside chat at 3:20 p.m. Eastern time.A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days.About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We'v
- PRLilly announces three acquisitions to build infectious disease portfolioAgreements with Curevo, LimmaTech Biologics and Vaccine Company address viral pathogens linked to long-term neurological and oncological risk, and bacterial pathogens that are difficult to prevent or treatAcquisitions build on Lilly's infectious disease legacy and reinforce its commitment to prevention strategies that reduce the long-term burden of serious diseaseINDIANAPOLIS, May 26, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced agreements to acquire three companies, Curevo Inc. (Curevo), LimmaTech Biologics AG (LimmaTech Biologics), and Vaccine Company, Inc. (Vaccine Company), that expand its research and development efforts into infectious disease. The transaction
- PRA single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemiaIn the Phase 1b Heart-2 trial, a single intravenous infusion of VERVE-102 produced dose-dependent lowering of PCSK9 and LDL-C, with both reductions sustained over follow-up of up to 18 months in participants at high risk for cardiovascular diseaseVERVE-102 is designed to mimic the protective effect of naturally occurring loss-of-function variants in PCSK9, which are associated with markedly lower lifetime risk of coronary heart diseaseLilly plans to begin enrolling the Phase 2 clinical study of VERVE-102 by the end of this yearINDIANAPOLIS, May 25, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced positive Phase 1b Heart-2 study results for VERVE-102, an investigational i
- PRPeptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness MarketsNEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The market for peptide-based health and performance products has been growing fast as more consumers focus on fitness, recovery, longevity, weight management, and overall wellness. Peptides are being widely explored for areas tied to muscle recovery, metabolic health, anti-aging research, and performance optimization. What used to be a niche biotech category is now attracting attention from wellness brands, pharmaceutical companies, and investors looking for exposure to one of the faster-growing areas of healthcare innovation. Those seeking high-growth opportunities in wellness and biotech should watch these c
- PRLilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trialIn TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥30% weight loss, a level long associated with bariatric surgery Individuals with a baseline BMI ≥35 who participated in a study extension continued to lose weight, and achieved up to an average of 85.0 lbs (30.3%) weight loss at 104 weeks At the 4 mg dose, reached with only a single escalation step, participants lost an average of 47.2 lbs (19.0%) at 80 weeks with a lower observed discontinuation rate due to adverse events vs. placeboINDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide) and Foundayo
- SECSEC Form 8-K filed by Eli Lilly and Company8-K - ELI LILLY & Co (0000059478) (Filer)
- INSIDERDirector Sulzberger Gabrielle was granted 5 shares, increasing direct ownership by 0.17% to 2,987 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Luciano Juan R was granted 16 shares, increasing direct ownership by 0.10% to 16,851 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Fyrwald J Erik was granted 10 shares, increasing direct ownership by 0.01% to 75,280 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Alvarez Ralph was granted 13 shares, increasing direct ownership by 0.02% to 55,627 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- PRLilly to participate in Bernstein's 42nd Annual Strategic Decisions ConferenceINDIANAPOLIS, May 18, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 28, 2026. Daniel M. Skovronsky, M.D., Ph.D., chief scientific and product officer, and president of Lilly Research Laboratories, will take part in a fireside chat at 1:30 p.m., Eastern time.A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days.About LillyLilly is a medicine company turning science into healing to make life better for
- PRLilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youthLilly to provide park and court to the City of Indianapolis as part of its 150th anniversary celebrationINDIANAPOLIS, May 16, 2026 /PRNewswire/ -- The Caitlin Clark Foundation, in partnership with Eli Lilly and Company (NYSE:LLY) and Musco Lighting, has opened three new multi-sport community courts across Indianapolis—creating year-round access to safe, high-quality spaces for youth to play. These latest court openings include two courts at Indianapolis Public Schools—Clarence Farrington and Edison School of the Arts—and a public court at the corner of E. South Street and S. New Jersey Street, that Lilly will provide to the City of Indianapolis and Indy Parks as part of its 150th anniversary
- PRLilly and UNICEF collaborate to give millions of children a healthier startSix-year initiative to improve non-communicable disease prevention and care for children in low- and middle-income countriesNEW YORK and INDIANAPOLIS, May 14, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and UNICEF USA announced today a collaboration aiming to improve non-communicable disease (NCD) prevention and care for children, reaching over 30 million young people and caregivers across 21 low- and middle-income countries.Marking its 150th anniversary, Lilly is committing $50 million to UNICEF USA, supporting UNICEF's efforts to strengthen primary healthcare systems to better prevent, detect and manage NCDs such as diabetes, congenital heart disease, sickle cell disease and resp
- PRLilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trialsIn ATTAIN-MAINTAIN, participants who transitioned from a maximum tolerated dose (MTD) of Wegovy (semaglutide) to Foundayo maintained all but 0.9 kg of their previously achieved weight loss on average after one yearIn ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN, participants who switched from Zepbound MTD to Foundayo or reduced the dose of Zepbound to 5 mg, respectively, maintained all but 5.0 kg and 5.6 kg of their previous weight loss on average after one yearParticipants in SURMOUNT-MAINTAIN who remained on Zepbound MTD for an additional year maintained all of their prior weight loss on averageINDIANAPOLIS, May 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced detailed re
- PRPeptide Wellness Market Could Near $300 Billion as Consumer Demand AcceleratesNEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary -- Investor interest in the next-generation wellness market is picking up fast as peptide-based health and performance products become more mainstream. More consumers are looking for wellness solutions that go beyond traditional supplements — products designed to support energy, recovery, metabolism, healthy aging, fitness, and overall well-being. As people become more focused on taking control of their health earlier in life, demand for science-backed peptide products continues to grow, creating major opportunities for companies developing high-quality formulations and modern wellness platforms. Investors looki
- SECSEC Form SD filed by Eli Lilly and CompanySD - ELI LILLY & Co (0000059478) (Filer)
- PRNYSE Content Update: Eli Lilly to Celebrate 150 Years of Scientific InnovationNYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, May 11, 2026 /CNW/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Ashley Mastronardi delivers the pre-market update on May 11thEquities are lower Monday morning after President Trump called an Iranian counteroffer to end the conflict in the Middle East 'totally unacceptable.'Intercontinental Exchange's (NYSE:ICE) Head of Mortgage and Housing Market Research Andy Walden will break down the May Mortgage Monitor on NYSE Live.Eli Lilly (NYSE:LLY)
- PRThe Next Generation of the GLP-1 Revolution Is Already UnderwayAUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (T2DM) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, SureNano Science Ltd. (CSE:SURE) (OTCQB:SURNF), (profile) through its subsidiary
- SECEli Lilly and Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - ELI LILLY & Co (0000059478) (Filer)
- INSIDERFormer 10% Shareholder Lilly Endowment Inc sold $15,754,537 worth of shares (15,828 units at $995.36), decreasing direct ownership by 0.02% to 91,881,150 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
LLY FAQ
7 questionsWhat does Eli Lilly and Company do?
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer...Where does LLY stock trade?
Eli Lilly and Company (LLY) is listed on NYSE.What sector and industry is LLY in?
Eli Lilly and Company operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.Does LLY pay a dividend?
LLY's most recent ex-dividend date was 2026-05-15 with a cash dividend of $1.73 per share. No future ex-date is on file yet.What are analysts saying about LLY?
Eli Lilly and Company has had 8 recent analyst actions on file. The most recent action was from HSBC Securities: Reduce on 2026-03-17.What companies are similar to LLY?
Notable peers in the same industry include AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), PFE (Pfizer Inc.), GSK (GSK plc). Compare LLY side-by-side with any of them on Quantisnow.How can I track LLY on Quantisnow?
Quantisnow aggregates Eli Lilly and Company's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LLY to receive live email and push alerts on every new disclosure.